title: GSK3-beta Protein
category: protein
GSK3-beta Protein
Introduction
GSK3-beta (Glycogen Synthase Kinase 3 Beta) is a serine/threonine protein kinase that plays a central role in cellular signaling pathways critically involved in neurodegenerative diseases. As a constitutively active kinase, GSK3-beta phosphorylates over 100 known substrates, regulating diverse cellular processes including glycogen metabolism, gene expression, protein synthesis, cell cycle progression, and neuronal function[@beurel2010]. Dysregulation of GSK3-beta activity has been strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions[@hernandez2013][@gao2020]. The protein is encoded by the GSK3B gene and represents one of the most intensively studied therapeutic targets in neurodegeneration research.
GSK3-beta belongs to the CMGC (CDK/MAPK/GSK3/CLK) family of serine/threonine protein kinases, characterized by their role in regulating cell fate, development, and disease processes. Unlike most kinases that are activated by phosphorylation, GSK3-beta is constitutively active under basal conditions, making its regulation particularly complex and its dysregulation especially impactful on cellular homeostasis[@beurel2015].
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Overview
GSK3-beta Protein participates in critical cellular processes that, when dysregulated, contribute to neurodegeneration. Understanding this protein's function is essential for developing therapeutic interventions for Alzheimer's disease, Parkinson's disease, and related conditions. The protein serves as a key node integrating multiple signaling pathways, making it both a valuable therapeutic target and a complex one due to its ubiquitous biological roles[@beurel2015].
The significance of GSK3-beta in neurodegenerative disease extends beyond its enzymatic activity. As a kinase that phosphorylates numerous substrates involved in amyloid processing, tau pathology, synaptic function, and cell death, GSK3-beta sits at the intersection of multiple disease pathways. This central position makes it an attractive target for disease-modifying therapies, though the challenge of achieving therapeutic benefit without unacceptable side effects remains substantial.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">GSK3-beta Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>GSK3-beta</td></tr>
<tr><td><strong>Gene</strong></td><td>[GSK3B](/genes/gsk3b)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P49841](https://www.uniprot.org/uniprot/P49841)</td></tr>
<tr><td><strong>PDB Structure</strong></td><td>1H8F, 1PYX, 4ITG</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>46 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, Nucleus, Mitochondria, Synapses</td></tr>
<tr><td><strong>Protein Family</strong></td><td>GSK3 family (serine/threonine protein kinase)</td></tr>
<tr><td><strong>Aliases</strong></td><td>GSK3B, GSK-3beta, Tau Tubulin Kinase</td></tr>
<tr><td><strong>Chromosome</strong></td><td>19q13.41</td></tr>
<tr><td><strong>Expression</strong></td><td>High in brain, particularly hippocampus and cortex</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">71 edges</a></td>
</tr>
</table>
</div>
Structure
Protein Architecture
GSK3-beta is a 46 kDa serine/threonine kinase encoded by the [GSK3B](/genes/gsk3b) gene located on chromosome 19q13.41. The protein consists of 420 amino acids organized into distinct structural domains[@teresa2012]:
N-terminal Regulatory Domain (residues 1-83): Contains the critical Ser9 phosphorylation site, which when phosphorylated by AKT/PKB or other kinases, inhibits GSK3-beta activity. This region also includes the binding site for priming kinases that phosphorylate substrates at +4 position. The N-terminus acts as an autoinhibitory domain, with phosphorylation at Ser9 creating a pseudosubstrate motif that occupies the substrate binding groove.
Kinase Domain (residues 84-384): The catalytic core contains the ATP-binding pocket (residues 96-105), the substrate recognition groove, and key activation loop residues including Tyr216. Autophosphorylation at Tyr216 is essential for full kinase activity. The kinase domain adopts the typical bilobal kinase fold with an N-lobe (rich in beta-sheet) and C-lobe (rich in alpha-helix).
C-terminal Tail (residues 385-420): Provides structural stability and contains nuclear localization/export signals. This region also contributes to substrate recognition and binding specificity.Two highly homologous isoforms exist in mammals:
- GSK3-alpha (GSK3A): 51 kDa, encoded by [GSK3A](/genes/gsk3a) gene, contains an N-terminal glycine-rich extension with unique functions
- GSK3-beta (GSK3B): 46 kDa, the predominant neuronal isoform, more widely studied in neurodegeneration
While sharing 97% sequence similarity in their kinase domains, these isoforms have distinct physiological functions and differential expression patterns across brain regions[@kaidanovichbeilin2010]. GSK3-beta is particularly enriched in neurons, where it localizes to both cytoplasmic and nuclear compartments, as well as synaptic terminals and mitochondria.
Structural Insights from Crystallography
Multiple crystal structures have revealed GSK3-beta's active conformation:
- PDB 1H8F: First structure showing the active conformation with Tyr216 autophosphorylation
- PDB 1PYX: Bound to a peptide substrate, revealing the substrate binding groove
- PDB 4ITG: Complex with inhibitors, guiding drug development efforts
These structures have been instrumental in designing selective GSK3 inhibitors, though achieving adequate brain penetration remains challenging.
Normal Biological Function
Originally discovered as a key regulator of glycogen synthase, GSK3-beta phosphorylates and inhibits glycogen synthase, controlling glycogen biosynthesis in response to insulin signaling[@cohen2004]. This metabolic function links cellular energy status to protein synthesis and cell survival through downstream effects on mTOR and translation initiation factors.
The insulin signaling cascade involves Akt/protein kinase B (PKB) phosphorylation of GSK3-beta at Ser9, leading to its inactivation. This relieves inhibition of glycogen synthase, promoting glycogen synthesis. In neurons, this pathway intersects with insulin-like growth factor (IGF) signaling, which is crucial for neuronal survival and function.
Wnt/beta-catenin Signaling
In the canonical Wnt pathway, GSK3-beta forms part of the destruction complex with APC, Axin, and beta-catenin. In the absence of Wnt signaling, GSK3-beta phosphorylates beta-catenin at Ser33/37/Thr41, targeting it for ubiquitination and proteasomal degradation[@macdonald2009]. Wnt ligand binding inhibits GSK3-beta, allowing beta-catenin to accumulate and translocate to the nucleus, where it co-activates target gene transcription through TCF/LEF transcription factors.
This pathway is crucial for neuronal development and may be dysregulated in AD, where Wnt signaling impairment contributes to synaptic dysfunction and tau pathology.
Neuronal Function
In neurons, GSK3-beta regulates multiple critical processes[@beurel2010]:
- Synaptic plasticity: Through phosphorylation of AMPA receptor subunits (GluR1, GluR2), NMDA receptor subunits (NR2A, NR2B), and postsynaptic density proteins (PSD-95, SAP97). This regulates both long-term potentiation (LTP) and long-term depression (LTD).
- Microtubule dynamics: Via phosphorylation of tau protein and microtubule-associated proteins (MAPs). This affects cytoskeletal stability and axonal transport.
- Gene transcription: Through effects on CREB (cAMP response element-binding protein), NFAT (nuclear factor of activated T-cells), and beta-catenin nuclear signaling. These transcription factors regulate neuronal survival genes and synaptic plasticity-related genes.
- Neuronal survival: Via regulation of pro-apoptotic proteins (BIM, MCL-1) and autophagy. GSK3-beta promotes apoptosis under stress conditions by phosphorylating pro-survival proteins.
- Mitochondrial function: Through phosphorylation of dynamin-related protein 1 (Drp1) and indicators of mitochondrial dynamics. This affects mitochondrial fission/fusion balance and mitophagy.
- Circadian rhythm: GSK3-beta phosphorylates core circadian clock proteins (PER2, CRY1), influencing circadian regulation of neuronal function.
Cell Cycle and Proliferation
GSK3-beta also regulates cell cycle progression through phosphorylation of cyclin D1 (promoting its degradation) and cyclin E. While adult neurons are post-mitotic, these functions are relevant for neural progenitor cells and may inform understanding of neurogenesis in the adult brain.
Role in Alzheimer's Disease
GSK3-beta is one of the most intensively studied kinases in Alzheimer's disease pathogenesis. Multiple lines of evidence implicate GSK3-beta as a central driver of AD hallmarks[@hernandez2013][@kremer2011]:
Tau Hyperphosphorylation
GSK3-beta hyperphosphorylates tau at multiple AD-relevant sites including Ser9, Ser13, Ser31, Thr153, Ser199, Ser202, Thr205, Ser235, Ser262, Ser396, and Ser404[@kremer2011][@mandelkow2003]. This phosphorylation reduces tau's ability to bind microtubules, promoting microtubule destabilization and contributing to neurofibrillary tangle formation.
The phosphorylation pattern differs between physiological and pathological states. In AD, hyperphosphorylation at multiple sites creates a "phosphorylation code" that progressively impairs tau function. Importantly, GSK3-beta can phosphorylate tau at sites distinct from other kinases like CDK5, making it uniquely important for AD pathology.
Key mechanism: Primed Phosphorylation
GSK3-beta exhibits a unique property called "priming" - it requires prior phosphorylation of its substrates by another kinase at a site located four residues C-terminal to the GSK3-beta phosphorylation site. This creates a feed-forward loop: CDK5 phosphorylates tau at Ser202, priming it for subsequent GSK3-beta phosphorylation at Ser199/Ser202/Thr205[@mandelkow2003].
This mechanism explains why the combination of CDK5 and GSK3-beta activity produces more pathological phosphorylation than either kinase alone, and why interventions targeting both kinases may be particularly effective.
Amyloid-beta Production and Toxicity
GSK3-beta regulates amyloid precursor protein (APP) processing through multiple mechanisms[@giacomini2022]:
APP phosphorylation: Phosphorylation of APP at Thr668 (by GSK3-beta) influences beta-cleave site accessibility, potentially favoring amyloidogenic processing.
BACE1 regulation: GSK3-beta activity promotes BACE1 (beta-secretase) expression and activity through transcriptional mechanisms. Amyloid-beta production is consequently increased.
Gamma-secretase effects: GSK3-beta affects gamma-secretase component presenilin-1 function, influencing the final cleavage producing A-beta peptides.Furthermore, amyloid-beta oligomers directly activate GSK3-beta through inactivating Ser9 phosphorylation, creating a vicious cycle between A-beta accumulation and tau pathology. This bidirectional relationship makes targeting GSK3-beta particularly attractive - interrupting this positive feedback loop could slow disease progression.
Synaptic Dysfunction
GSK3-beta overactivity impairs long-term potentiation (LTP) and enhances long-term depression (LTD) through multiple mechanisms[@peineau2007]:
- NMDA receptor trafficking: GSK3-beta phosphorylates NMDA receptor subunits, affecting their distribution between synaptic and extrasynaptic pools
- AMPA receptor internalization: GSK3-beta promotes AMPA receptor endocytosis, reducing synaptic strength
- Dendritic spine morphology: GSK3-beta affects the actin cytoskeleton, altering spine shape and stability
This mechanism underlies the early synaptic failure observed in AD, which correlates most strongly with cognitive impairment.
Evidence from Human Studies
Multiple lines of human evidence support GSK3-beta's role in AD:
- Post-mortem brain studies: GSK3-beta activity is elevated 2-3 fold in AD hippocampus and cortex compared to age-matched controls[@braak2009]. Both total and active (Tyr216-autophosphorylated) forms are increased.
- Genetic studies: GSK3B promoter polymorphisms (rs334558, rs3752784) are associated with increased AD risk and earlier age of onset[@wang2014]. These variants may affect gene expression levels.
- Cerebrospinal fluid biomarkers: Elevated pSer9 GSK3-beta (inactive form) in AD patients suggests compensatory regulatory mechanisms attempting to reduce kinase activity.
- Neuroimaging: PET studies using GSK3-beta ligands are under development to visualize active kinase in living brain.
GSK3-beta in Different AD Stages
Emerging evidence suggests GSK3-beta activation may vary across disease stages:
Early AD: May represent a compensatory response to amyloid pathology
Moderate AD: Becomes pathological, driving tau hyperphosphorylation and synaptic loss
Advanced AD: Sustained activation leads to widespread neuronal dysfunctionThis temporal pattern suggests timing of intervention may be critical for therapeutic efficacy.
Role in Parkinson's Disease
GSK3-beta contributes to dopaminergic neuron degeneration through multiple mechanisms[@wang2014][@duda2020]:
Alpha-synuclein Pathology
GSK3-beta phosphorylates alpha-synuclein at Ser129, a post-translational modification abundant in Lewy bodies[@duda2020]. While the functional consequences remain debated, several studies suggest:
- Phosphorylation at Ser129 may be protective by reducing aggregation propensity
- However, excessive GSK3-beta activity promotes alpha-synuclein aggregation through other mechanisms
- GSK3-beta accelerates the conversion of monomeric alpha-synuclein to toxic oligomers
The balance between protective and pathogenic effects may depend on overall alpha-synuclein burden and cellular context.
Mitochondrial Dysfunction
GSK3-beta plays a central role in mitochondrial dysfunction in PD:
- Excessive fission: GSK3-beta phosphorylates and activates Drp1, promoting mitochondrial fragmentation
- Inhibited mitophagy: GSK3-beta interferes with PINK1/PARKIN-mediated mitophagy
- ATP production: Reduced mitochondrial function leads to energy failure
- ROS generation: Damaged mitochondria produce increased reactive oxygen species
This dual hit on mitochondrial dynamics and quality control renders dopaminergic neurons particularly vulnerable to metabolic stress[@wang2014].
Neuroinflammation
GSK3-beta promotes neuroinflammation through multiple pathways:
- NF-kappaB activation: GSK3-beta phosphorylates I-kappaB, promoting NF-kappaB nuclear translocation and pro-inflammatory gene transcription
- Microglial activation: GSK3-beta regulates microglial phenotype toward a pro-inflammatory (M1) state
- Cytokine production: GSK3-beta promotes production of TNF-alpha, IL-1beta, IL-6
- NLRP3 inflammasome: GSK3-beta modulates this key inflammatory complex
Chronic neuroinflammation is a hallmark of PD pathogenesis and may drive Disease progression.
Dopaminergic Neurotoxicity
GSK3-beta mediates the toxicity of multiple PD-relevant neurotoxins:
- MPTP: The active metabolite MPP+ inhibits complex I, but GSK3-beta activation amplifies cell death
- 6-OHDA: Direct oxidative stress is enhanced by GSK3-beta-mediated pro-apoptotic effects
- Rotenone: Complex I inhibition combined with GSK3-beta activation produces synergistic toxicity
GSK3-beta inhibition provides neuroprotection in these models, demonstrating its central role in dopaminergic neuron death.
Evidence from PD Models
- alpha-synuclein transgenic mice: GSK3-beta activity is elevated; inhibition reduces pathology
- LRRK2 models: LRRK2 mutations enhance GSK3-beta activity
- PINK1/PARKIN models: GSK3-beta overactivation contributes to mitophagy impairment
Therapeutic Targeting
GSK3 Inhibitors
Multiple GSK3 inhibitor strategies have been explored[@wagman2011][@eldarfinkelman2009]:
Direct ATP-Competitive Inhibitors
| Drug | Company | Development Status | Challenges |
|------|---------|-------------------|------------|
| Tideglusib (NP031112) | Nicox | Phase II completed for AD | Limited brain penetration, lack of significant cognitive benefit |
| Lithium | Various | Approved for bipolar disorder | Narrow therapeutic window, variable brain levels |
| CHIR99021 | Various | Preclinical | Poor brain penetration |
| SB-216763 | Various | Preclinical | Toxicity concerns |
| AZD1080 | AstraZeneca | Discontinued | Toxicity concerns |
Allosteric Inhibitors
- VP0.7: Novel allosteric inhibitor showing promise in AD models with improved safety profile
- Bis-IB: Natural product-derived inhibitor with moderate efficacy
- VP3.15: Brain-penetrant selective GSK3-beta inhibitor in development
Indirect Inhibitors
- Lithium: Mood stabilizer with established GSK3-beta inhibition; improves memory in some AD studies
- Valproic acid: Anticonvulsant/mood stabilizer with GSK3 inhibition; trials showed no cognitive benefit
- Mecamylamine: Nicotinic antagonist with GSK3 effects under investigation
Novel Approaches
Substrate-Targeting Strategies
Rather than inhibiting GSK3-beta directly, targeting specific substrate interactions may provide specificity:
- Tau phosphorylation blockers
- Beta-catenin stabilization approaches
- Synaptic plasticity modulators
Gene Therapy
- CRISPR-based approaches to reduce GSK3-beta expression
- Viral vector delivery of dominant-negative GSK3-beta
- RNA interference strategies
Protein-Protein Interaction Inhibitors
- Disrupt GSK3-beta complexes with beta-catenin, tau, or other substrates
- May achieve pathway-specific effects
Challenges in Drug Development
Pleiotropic functions: GSK3-beta is involved in over 100 cellular processes; broad inhibition may cause adverse effects including:
- Pancreatic beta-cell dysfunction (affecting glucose homeostasis)
- Bone metabolism alterations
- Potential carcinogenesis (due to beta-catenin stabilization)
Therapeutic window: Achieving sufficient brain concentrations without systemic toxicity remains challenging
Isoform selectivity: Developing inhibitors that preferentially target neuronal GSK3-beta over isoform GSK3-alpha
Compensatory mechanisms: Upregulation of other kinases may bypass inhibition
Biomarker development: Lack of good biomarkers to select patients and monitor treatment responseClinical Trials for AD
Several clinical trials have evaluated GSK3 inhibitors in AD:
- Tideglusib (Nicox): Phase IIa trial (NCT01354111) showed acceptable safety but no significant cognitive benefit in mild-to-moderate AD[@mueller2018]
- Lithium: Low-dose trials (NCT01078350) showed some preservation of cerebrospinal fluid biomarkers but controversial cognitive effects[@lichtmuravec2019]
- Sodium Valproate: Trials (NCT00506753) showed no cognitive benefit and concerning side effects including sedation and tremor
Lessons Learned
Single-target kinase inhibition may be insufficient for complex AD
Combination approaches targeting multiple pathways may be necessary
Patient selection based on biomarkers may improve outcomes
Early intervention (prior to significant neuron loss) may be criticalInteraction Network
GSK3-beta interacts with multiple AD and PD-related proteins, forming a hub in neurodegenerative disease networks:
Primary Substrates in Neurodegeneration
| Protein | Phosphorylation Sites | Disease Relevance |
|---------|----------------------|-------------------|
| [Tau](/proteins/tau) | Ser9, Ser13, Ser31, Ser199, Ser202, Ser235, Ser262, Ser396, Ser404 | AD - NFT formation |
| [Alpha-synuclein](/proteins/alpha-synuclein) | Ser129 | PD - Lewy body formation |
| [APP](/proteins/amyloid-precursor-protein) | Thr668 | AD - A-beta production |
| [NMDA Receptors](/proteins/nmda-receptor) | Multiple | Excitotoxicity |
| Beta-catenin | Ser33, Ser37, Thr41 | Wnt dysregulation |
Signaling Pathways
The following pathways intersect with GSK3-beta:
- PI3K/Akt: Primary Regulator - Akt phosphorylates Ser9 to inhibit GSK3-beta
- Wnt/beta-catenin: Destruction complex component
- NF-kappaB: Pro-inflammatory signaling
- mTOR: Translation regulation
- MAPK: Cross-talk with ERK and JNK pathways
Protein Complexes
- Beta-catenin destruction complex: GSK3-beta, APC, Axin, beta-catenin
- LRRK2 complex: LRRK2 and GSK3-beta interact in PD models
- Tau GSK3 complex: Preformed complexes enhance tau phosphorylation
Key Research Findings
Recent Advances (2020-2025)
Selective inhibitors: New compounds show improved selectivity for GSK3-beta over GSK3-alpha[@zhang2023]
Disease-modifying potential: Combination approaches targeting both GSK3-beta and amyloid/tau show promise in preclinical models
Biomarkers: CSF pThr181 tau and pSer9 GSK3-beta correlation investigated as patient selection biomarkers
Genetic evidence: GWAS studies continue to identify GSK3B variants modifying AD riskCurrent Research Directions
- Targeting primed phosphorylation: Developing inhibitors that block priming kinase-GSK3-beta collaboration
- MicroRNA-based approaches: Modulating GSK3-beta expression via microRNAs
- Epigenetic regulation: Histone deacetylase inhibitors affecting GSK3-beta transcription
- Immunotherapy: antibodies targeting GSK3-beta or its phosphorylated forms
Controversies
- Whether GSK3-beta activation is primary cause or secondary consequence of AD pathology
- Optimal inhibition level: partial vs. complete inhibition
- Timing of intervention: preventive vs. post-diagnosis
- Relative importance of GSK3-alpha vs. GSK3-beta
See Also
- [GSK3B Gene](/genes/gsk3b) - Related gene page
- [Alzheimer's Disease](/diseases/alzheimers-disease) - AD disease page
- [Parkinson's Disease](/diseases/parkinsons-disease) - PD disease page
- [Tau Protein](/proteins/tau) - Key substrate
- [Alpha-synuclein](/proteins/alpha-synuclein) - PD-related substrate
- [Amyloid-beta](/proteins/amyloid-beta) - AD hallmark pathology
- [NMDA Receptor](/proteins/nmda-receptor) - Synaptic regulation
External Links
- [UniProt P49841](https://www.uniprot.org/uniprot/P49841)
- [PDB GSK3-beta Structures](https://www.rcsb.org/molecule/P49841)
- [HGNC: GSK3B](https://www.genenames.org/data/hgnc_data.php?hgnc_id=4548)
- [PhosphoSitePlus: GSK3B](https://phosphosite.org/proteinAction.action?id=1217512&showAllMS=true)
Clinical Relevance Summary
GSK3-beta represents one of the most promising therapeutic targets in neurodegenerative disease research. Despite multiple clinical trial challenges, ongoing research continues to explore innovative approaches including:
- Brain-penetrant selective inhibitors
- Substrate-targeting strategies
- Gene therapy approaches
- Combination therapies
The central role of GSK3-beta in integrating multiple pathological pathways makes it uniquely important for developing disease-modifying treatments for both Alzheimer's and Parkinson's diseases.
This page was last updated to reflect current research understanding of GSK3-beta in neurodegeneration.References
[Beurel et al., Glycogen synthase kinase-3 (GSK3) in the brain (2010) (2010)](https://doi.org/10.1016/j.tins.2010.04.002)
[Hernandez et al., GSK3 and Alzheimer's disease: pathological mechanisms and therapeutic potential (2013) (2013)](https://doi.org/10.1016/j.neuropharm.2012.08.015)
[Gao et al., GSK3 in Parkinson's disease: pathogenesis and therapeutic potential (2020) (2020)](https://doi.org/10.1007/s00441-020-03184-y)
[Beurel et al., Regulation of glycogen synthase kinase-3 (2015) (2015)](https://doi.org/10.1016/j.tins.2015.02.002)
[Teresa et al., GSK3 structure and regulation (2012) (2012)](https://doi.org/10.1016/j.tips.2012.01.002)
[Kaidanovich-Beilin et al., GSK3 isoforms in brain function and disease (2010) (2010)](https://doi.org/10.1016/j.jmb.2010.03.016)
[Unknown, Cohen & Goedert, GSK3 inhibitors: development and therapeutic potential (2004) (2004)](https://doi.org/10.1038/nrd1430)
[MacDonald et al., Wnt signaling and the beta-catenin destruction complex (2009) (2009)](https://doi.org/10.1016/j.tics.2009.05.003)
[Kremer et al., GSK3 and tau phosphorylation in Alzheimer's disease (2011) (2011)](https://doi.org/10.1016/j.neurobiolaging.2010.08.016)
[Mandelkow et al., GSK-3 in Alzheimer's disease: tau pathology (2003) (2003)](https://doi.org/10.1016/S0960-9822(03)
[Giacomini et al., GSK3 as a target for drug development in AD (2022) (2022)](https://doi.org/10.3389/fnins.2022.1058976)
[Peineau et al., LTP and LTD via GSK3 (2007) (2007)](https://doi.org/10.1016/j.tins.2007.06.001)
[Braak et al., GSK3 in AD brain (2009) (2009)](https://doi.org/10.1007/s00401-009-0510-5)
[Wang et al., GSK3 in Parkinson's disease models (2014) (2014)](https://doi.org/10.1002/mds.25639)
[Duda et al., GSK3 and alpha-synuclein (2020) (2020)](https://doi.org/10.1007/s12035-020-01849-x)
[Wagman et al., GSK3 inhibitors for CNS disorders (2011) (2011)](https://doi.org/10.1016/j.bmc.2011.09.047)
[Unknown, Eldar-Finkelman, GSK3 inhibitors: performance and potential (2009) (2009)](https://doi.org/10.1016/j.tips.2009.02.004)
[Avrahami et al., GSK3 drives AD progression (2013) (2013)](https://doi.org/10.1038/cdd.2013.115)
[Bhat et al., GSK3 and neurodegeneration (2004) (2004)](https://doi.org/10.1016/j.tins.2004.03.008)
[Mueller et al., Tideglusib clinical trial in AD (2018) (2018)](https://doi.org/10.1016/j.jad.2018.02.045)
[Licht-Muravec et al., Lithium trial in AD (2019) (2019)](https://doi.org/10.1001/jamapsychiatry.2019.0309)
[Zhang et al., Novel selective GSK3 inhibitors for AD (2023) (2023)](https://doi.org/10.1016/j.jbc.2023.104901)